Clinical trial data are the gold standard for evaluating pharmaceutical safety and efficacy. There is an ethical and scientific imperative for transparency and data sharing to confirm published results and generate new knowledge. The Open Translational Science in Schizophrenia (OPTICS) Project was an open-science initiative aggregating Janssen clinical trial and NIH/NIMH data from real-world studies and trials in schizophrenia. The project aims were to show the value of using shared data to examine: therapeutic safety and efficacy; disease etiologies and course; and methods development. The success of project investigators was due to collaboration from project applications through analyses, with support from the Harvard Catalyst. Project work was independent of Janssen; all intellectual property was dedicated to the public. Efforts such as this are necessary to gain deeper insights into the biology of disease, foster collaboration, and to achieve the goal of developing better treatments, reducing the overall public health burden of devastating brain diseases.

临床试验数据是评估药物安全性和有效性的金标准。透明度和数据共享需要道德和科学的要求，以确认已发表的结果并产生新的知识。精神分裂症开放式转化科学（OPTICS）项目是一项开放性科学计划，汇集了Janssen临床试验和来自精神分裂症实际研究和试验的NIH / NIMH数据。该项目的目的是展示使用共享数据进行检查的价值：治疗安全性和有效性；病因和病程；和方法开发。项目研究人员的成功归功于在哈佛催化剂的支持下，从项目应用程序到分析之间的协作。项目工作独立于Janssen；所有的知识产权都是献给公众的。